CHARACTERISTICS OF WATER-SOLUBLE AND LIPOSOMAL QUERCETINE ON THE WEIGHT MEASURING VALUES, CARDIAC INTERVALOGRAM PARAMETERS AND TOLERANCE TO PHYSICAL LOAD OF ANIMALS IN TYPE 2 DIABETES MELLITUS WITH CONCOMITANT OBESITY

Authors

  • Stechyshyn I. P. State Higher Educational Establishment I. Ya. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2015.4.10

Keywords:

diabetes mellitus, obesity, heart, quercetine

Abstract

The model of type 2 diabetes mellitus with concomitant obesity (single injection of streptozotocine, 30 mg/kg, after four-week keeping on high-fat diet) provided a basis for the study of water-soluble and liposomal quercetine efficacy (10 mg/kg, introduction starting 10 weeks after streptozotocine injection and lasting 14 days). Body weight and heart weight changes as well as the correlation of the values (heart weight ratio) were investigated. The exercise tolerance was determined through swimming test and cardiac intervalography was registered. Body weight as well as heart weight and heart weight ratio were found to grow in the animals with type 2 diabetes mellitus and concomitant obesity, whereas the exercise tolerance was found to decrease. Cardiac intervalogram findings revealed disbalanced parasympathetic and sympathetic influence on the heart and insufficient centralization of cardiac rhythm control. Drug injection was found to contribute to the improvement of weight measuring values, exercise tolerance and keeping the balance of cardiac intervalography values. The liposomal quercetine form was found to possess higher efficacy, as compared with the water-soluble one.

References

Dolzhenko MM, Perepel’chenko NA, Bazylevych AJa. Ishemichna hvoroba sercja na tli cukrovogo diabetu 2 typu: svojeridnist’ perebigu ta obgruntuvannja terapii’, Kyiv, 2010: 73 p.

Opie LH, Yellon DM, Gersh BJ. Heart 2011; 97:6-14.

Jaiswal N, Rizvi SI. Cell Membran Free Radical Res 2011; 3(2):171-177.

Shhokina KG, Shtrygol’ SJu, Stoljetov JuV, et al. Visnyk Farmacii’ 2010; 3(63):79-82.

Hyzhnja JaV, Borikov OJu, Ataman JuO. Visnyk SumDU. Serija Medycyna 2010; 1:37-41.

Zupanec’ KO, Otrishko IA. Visnyk Farmacii’ 2010;1(61):69-71.

Nechipaj ZhA. Endotelial’na dysfunkcija ta funkcional’no-morfologichni zminy shlunka u hvoryh na cukrovyj diabet, sposoby dyferencijovanoi’ korekcii’, Kyi’v, 2010: 23 p.

Aguirre L, Arias N, Macarulla MT, et al. Open Nutraceuticals J 2011; 4:189-198.

Bjelik GV. Eksperymental’ne obgruntuvannja vykorystannja liposomal’noi’ formy kvercetynu pry sercevo-sudynnyh zahvorjuvannjah, Harkiv, 2006: 25 p.

Kihtjak OP, Neshheret OP. Eksperymental’na ta Klinichna Fiziologija i Biohimija 2011; 1:16-23.

Patent 92289. Sposib modeljuvannja eksperymental’nogo ozhyrinnja 2014; 15: 4 p.

Chekman IS, Dacjuk NO, Luk’janova OM, et al. Liky Ukrai’ny 2008; 6(122):76-81.

Zupanec’ IA, Shebeko SK, Harchenko DS. Farmakologija ta Likars’ka Toksykologija 2009; 1(8):28-32.

Orlovskij MA. Patologija 2004; 1(1):52-56.

Baevskij RM, Ivanov GG, Chirejkin LV, et al. Vestn Aritmol 2001; 24:65-87.

Kotel’nikov SA, Nozdrachev AD, Odinak MM, et al. Fiziologija Cheloveka 2002; 28(1):130-143.

Goncharov SI, Kuz’menko SD. Gigiena i Sanitarija 1991; 4:25-27.

Dubilej TA, Badova TA, Migovan SA, et al. Problemy Starenija i Dolgoletija 2007; 16(1):11-20.

Rogovs’kij VS, Shimanovs’kij NL, Matjushin AI. Jeksperimental’naja i Klinicheskaja Farmakologija 2012; 75(9):37-41.

Babenko SV, Li AV, Bondar LV, et al. Ukr Zhurn Ekstremal’noi’ Medycyny im. G. O. Mozhajeva 2011; 12(4):144-150.

Downloads

Published

2015-12-03

How to Cite

Stechyshyn, I. P. (2015). CHARACTERISTICS OF WATER-SOLUBLE AND LIPOSOMAL QUERCETINE ON THE WEIGHT MEASURING VALUES, CARDIAC INTERVALOGRAM PARAMETERS AND TOLERANCE TO PHYSICAL LOAD OF ANIMALS IN TYPE 2 DIABETES MELLITUS WITH CONCOMITANT OBESITY. Problems of Endocrine Pathology, 54(4), 79-86. https://doi.org/10.21856/j-PEP.2015.4.10